Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Oct 15, 2026 · Source: ClinicalTrials.gov
The study is currently accepting participants.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Alliance Foundation Trials, LLC.
- Interventions being studied
- Drug: Durvalumab 50 MG/ML
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Age ≥ 18 years.
- Body weight \>30 kg.
- Must have a life expectancy of at least 12 weeks.
- Must have histologically or cytologically confirmed diagnosis of pathologic T1-T2 N0-1 M0 small-cell lung cancer per the American Joint Committee on Cancer staging system, 8th edition.
- Have completely resected (wedge resection, segmentectomy, lobectomy, sleeve lobectomy, bilobectomy, or pneumonectomy) small-cell lung cancer within 78 days of enrollment.
- Complete mediastinal lymph node dissection (MLND) or systematic mediastinal lymph node sampling is required.
- No prior systemic therapies, for small cell lung cancer.
- Post-operative radiation for the resected small cell lung cancer is acceptable per treating physician in the setting of N1 disease, but no other prior radiation for small cell lung cancer.
- ECOG performance status 0-1.
- Patients who are receiving any other investigational agents.
- Concurrent enrollment in another clinical study involving investigational treatment directed to treatment of patients with small cell lung cancer.
- Prior treatment with durvalumab.
- History of another primary malignancy except for:
- Malignancy treated with curative intent and with no known active disease ≥2 years before the first dose of IP and of low potential risk for recurrence.
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
- Superficial bladder cancer without active disease after treatment.
- Low grade prostate cancer without indication for active treatment.
- Adequately treated carcinoma in situ without evidence of disease.
- Patients with a history of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or insufficiently treated deep venous thrombosis (DVT) within the past 3 months.
- Patients with hemoptysis in excess of 2.5 mL within 2 weeks prior to the first dose of study medication.
- Patients requiring concomitant therapy with phenytoin, phenobarbital, or carbamazepine.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Illinois ChicagoChicago, Illinois
- Maine Medical CenterScarborough, Maine
- Massachusetts General Hospital (MGH)Boston, Massachusetts
- Dana Farber Cancer InstituteBoston, Massachusetts
- Washington University in St. Louis School of MedicineSt Louis, Missouri
- University of Virginia Comprehensive Cancer CenterCharlottesville, Virginia
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 15, 2026. Always confirm current availability with the study team.